185 related articles for article (PubMed ID: 22349825)
1. Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma.
Kikuchi K; Soundararajan A; Zarzabal LA; Weems CR; Nelon LD; Hampton ST; Michalek JE; Rubin BP; Fields AP; Keller C
Oncogene; 2013 Jan; 32(3):286-95. PubMed ID: 22349825
[TBL] [Abstract][Full Text] [Related]
2. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis.
Regala RP; Davis RK; Kunz A; Khoor A; Leitges M; Fields AP
Cancer Res; 2009 Oct; 69(19):7603-11. PubMed ID: 19738040
[TBL] [Abstract][Full Text] [Related]
3. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.
Butler AM; Scotti Buzhardt ML; Erdogan E; Li S; Inman KS; Fields AP; Murray NR
Oncotarget; 2015 Jun; 6(17):15297-310. PubMed ID: 25915428
[TBL] [Abstract][Full Text] [Related]
4. Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells.
Regala RP; Thompson EA; Fields AP
Cancer Res; 2008 Jul; 68(14):5888-95. PubMed ID: 18632643
[TBL] [Abstract][Full Text] [Related]
5. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Ciota.
Erdogan E; Lamark T; Stallings-Mann M; Lee Jamieson ; Pellecchia M; Thompson EA; Johansen T; Fields AP
J Biol Chem; 2006 Sep; 281(38):28450-9. PubMed ID: 16861740
[TBL] [Abstract][Full Text] [Related]
6. A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.
Stallings-Mann M; Jamieson L; Regala RP; Weems C; Murray NR; Fields AP
Cancer Res; 2006 Feb; 66(3):1767-74. PubMed ID: 16452237
[TBL] [Abstract][Full Text] [Related]
7. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.
Phillips E; Lang V; Bohlen J; Bethke F; Puccio L; Tichy D; Herold-Mende C; Hielscher T; Lichter P; Goidts V
Int J Cancer; 2016 Oct; 139(8):1776-87. PubMed ID: 27299852
[TBL] [Abstract][Full Text] [Related]
8. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
9. Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma.
Yin N; Liu Y; Khoor A; Wang X; Thompson EA; Leitges M; Justilien V; Weems C; Murray NR; Fields AP
Cancer Cell; 2019 Aug; 36(2):156-167.e7. PubMed ID: 31378680
[TBL] [Abstract][Full Text] [Related]
10. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
11. Targeting the oncogenic protein kinase Ciota signalling pathway for the treatment of cancer.
Fields AP; Frederick LA; Regala RP
Biochem Soc Trans; 2007 Nov; 35(Pt 5):996-1000. PubMed ID: 17956262
[TBL] [Abstract][Full Text] [Related]
12. Recurrent copy number gains drive PKCι expression and PKCι-dependent oncogenic signaling in human cancers.
Liu Y; Justilien V; Fields AP; Murray NR
Adv Biol Regul; 2020 Dec; 78():100754. PubMed ID: 32992230
[TBL] [Abstract][Full Text] [Related]
13. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota.
Guo W; Wu S; Liu J; Fang B
Cancer Res; 2008 Sep; 68(18):7403-8. PubMed ID: 18794128
[TBL] [Abstract][Full Text] [Related]
14. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma.
Kim KH; Chung C; Kim JM; Lee D; Cho SY; Lee TH; Cho HJ; Yeo MK
BMC Cancer; 2019 Aug; 19(1):804. PubMed ID: 31412817
[TBL] [Abstract][Full Text] [Related]
17. Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids.
Linch M; Sanz-Garcia M; Rosse C; Riou P; Peel N; Madsen CD; Sahai E; Downward J; Khwaja A; Dillon C; Roffey J; Cameron AJ; Parker PJ
Carcinogenesis; 2014 Feb; 35(2):396-406. PubMed ID: 24072773
[TBL] [Abstract][Full Text] [Related]
18. PKC iota promotes cellular proliferation by accelerated G1/S transition via interaction with CDK7 in esophageal squamous cell carcinoma.
Ni S; Chen L; Li M; Zhao W; Shan X; Wu M; Cheng J; Liang L; Wang Y; Jiang W; Zhang J; Ni R
Tumour Biol; 2016 Oct; 37(10):13799-13809. PubMed ID: 27481515
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
20. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation.
Justilien V; Fields AP
Oncogene; 2009 Oct; 28(41):3597-607. PubMed ID: 19617897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
